Abstract:The use of existing mouse models in cancer research is of utmost importance as they aim to explore the casual link between candidate cancer genes and carcinogenesis as well as to provide models to develop and test new therapies. However, faster progress in translating mouse cancer model research into the clinic has been hampered due to the limitations of these models to better reflect the complexities of human tumors. Traditionally, immunocompetent and immunodeficient mice with syngeneic and xenografted tumors transplanted subcutaneously or orthotopically have been used. These models are still being widely employed for many different types of studies, in part due to their widespread availability and low cost. Other types of mouse models used in cancer research comprise transgenic mice in which oncogenes can be constitutively or conditionally expressed and tumor-suppressor genes silenced using conventional methods, such as retroviral infection, microinjection of DNA constructs, and the so-called "gene-targeted transgene" approach. These traditional transgenic models have been very important in studies of carcinogenesis and tumor pathogenesis, as well as in studies evaluating the development of resistance to therapy. Recently, the clustered regularly interspaced short palindromic repeats (CRISPR)-based genome editing approach has revolutionized the field of mouse cancer models and has had a profound and rapid impact on the development of more effective systems to study human cancers. The CRISPR/Cas9-based transgenic models have the capacity to engineer a wide spectrum of mutations found in human cancers and provide solutions to problems that were previously unsolvable. Recently, humanized mouse xenograft models that accept patient-derived xenografts and CD34+ cells were developed to better mimic tumor heterogeneity, the tumor microenvironment, and cross-talk between the tumor and stromal/immune cells. These features make them extremely valuable models for the evaluation of investigational cancer therapies, specifically new immunotherapies. Taken together, improvements in both the CRISPR/Cas9 system producing more valid mouse models and in the humanized mouse xenograft models resembling complex interactions between the tumor and its environment might represent one of the successful pathways to precise individualized cancer therapy, leading to improved cancer patient survival and quality of life.

Novel Approaches to Identify Low-Penetrance Cancer Susceptibility Genes Using Mouse Models.

Genomic approaches to identification of tumour-susceptibility genes using mouse models.

Candidate lung tumor susceptibility genes identified through whole-genome association analyses in inbred mice.

Transgenic Murine Models of Human Cancer: Bridging the Gap from Mouse to Man

Mouse Models for Multistep Tumorigenesis

Mouse models of DNA mismatch repair in cancer research

Conditional mouse models of sporadic cancer

Mouse Models of BRCA1 and Their Application to Breast Cancer Research

Mouse Systems Genetics as a Prelude to Precision Medicine

Principles for the post-GWAS functional characterization of cancer risk loci

Data from Genome-Wide Association and Fine Mapping of Genetic Loci Predisposing to Colon Carcinogenesis in Mice

If you give a mouse a mutation: comparing the therapeutic utility of renowned mouse models of human cancers

Analyses of Tumor-Suppressor Genes in Germline Mouse Models of Cancer

Conditional Knockout Mouse Models of Cancer

Transgenic Mouse Models in Cancer Research

Transposon Insertional Mutagenesis In Mice Identifies Human Breast Cancer Susceptibility Genes And Signatures For Stratification

Low-Penetrance Susceptibility Variants in Colorectal Cancer-Current Outlook in the Field

Genetic Background Controls Tumor Development In Pten-Deficient Mice

Data from Genetic Background Controls Tumor Development in <i>Pten</i>-Deficient Mice

Mouse Models for Human DNA Mismatch-Repair Gene Defects.

Humanized mouse models: A valuable platform for preclinical evaluation of human cancer